QuidelOrtho Corporation (QDEL) Earnings Call Transcripts

QuidelOrtho Corporation's Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, QuidelOrtho Corporation reported total revenue of $620 million, reflecting a significant decline in respiratory revenue due to a milder flu season, which was down approximately 30% year-over-year. The company has adjusted its full-year revenue guidance to a range of $2.7 billion to $2.75 billion, primarily impacted by respiratory season weakness and anticipated changes in China’s IVD pricing guidelines. Adjusted EBITDA for the quarter was $109 million, with a margin of 18%, and management expects to improve margins and cash flow in the second half of the year as new product launches ramp up.

Reported metrics

Guidance from management

Management has lowered its full-year revenue guidance to $2.7 billion to $2.75 billion, reflecting expected challenges in the respiratory market and China. They maintain an adjusted EBITDA margin target of 23% for the year.

What management said

Yes, as, hey Jack, as noted in the prepared remarks, we do expect that sequentially Q2 will be relatively flat with Q1, but will provide growth year-over-year. The growth is going to come from the core business, as you think about the labs business and the IH business and the Triage business, that growth versus prior year.

Hey, Andrew. I do think that what we're looking at in the guide as you think about first half, second half, is that we are expecting the revenue growth to pick up quite a bit in the second half versus the first half. That's really a function of we expect that the China impacts that we've talked about in the prepared remarks generally are going to happen in the first half of the year and not so much in the second hal...

What analysts pressed on

Analysts expressed concerns regarding the impact of the respiratory season on revenue and the potential long-term effects of the pricing changes in China. There were inquiries about the company's strategies to mitigate these headwinds and the sustainability of growth in the labs business amidst these challenges.

Main topics on the call

• Revenue Decline Due to Respiratory Season — QuidelOrtho experienced a significant decline in respiratory revenue, which totaled $68 million, down from the previous year due to a 'significantly softer respiratory season' and a 30% drop in ILI visits. Management not...
• China Market Headwinds — Management highlighted that sales in China slowed as distributors paused purchases ahead of new IVD pricing guidelines, which are expected to impact about half of their sales. They indicated that 'the business continues ...
• Acquisition of LEX Diagnostics — The acquisition of LEX Diagnostics was completed in April, adding a 'highly differentiated, ultra-fast molecular platform' that is expected to drive future growth. Management has seen strong customer interest and anticip...
• Adjusted EBITDA and Margin Outlook — Adjusted EBITDA for Q1 was $109 million, with an 18% margin. Management expects to improve adjusted EBITDA margins to 23% for the full year, driven by cost-saving initiatives and new product launches.

Read the full QuidelOrtho Corporation transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 66 QuidelOrtho Corporation earnings call transcripts on record, spanning January 15, 2020 to August 6, 2026. Based on this history, QuidelOrtho Corporation reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

QDEL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

66

First call

January 15, 2020

Most recent

August 6, 2026

Reporting cadence

quarterly